Ivabradine Aurovitas (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a controlled reduction of resting heart rate without affecting myocardial contractile force.

The appropriate dose of ivabradine is determined by the prescribing clinician based on the individual’s clinical condition, heart‑rate target, and tolerance. Dosage adjustments may be required during therapy, and patients should follow the specific instructions provided by their healthcare professional.

Safety data for ivabradine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers must evaluate each case individually and discuss alternatives when appropriate.

To request Ivabradine Aurovitas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also lower blood pressure, whereas ivabradine selectively inhibits the If current without affecting contractility or blood pressure. Ivabradine may be chosen when beta‑blockers are contraindicated or not tolerated.

Ivabradine Aurovitas tablets should be stored at temperatures below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Ivabradine Aurovitas is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, chewed, or crushed. Dosing times are typically scheduled to maintain consistent plasma concentrations, as directed by the prescribing clinician.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may be persistent. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering agents.

Ivabradine is contraindicated in patients with severe sinus node dysfunction, second‑degree or higher atrioventricular block, a resting heart rate below 60 bpm, acute decompensated heart failure, or in those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.